JHS Svendgaard Laboratories Limited JHS NSE
Company Overview
JHS Svendgaard Laboratories Limited, together with its subsidiaries, manufactures, trades in, and sells a range of oral and dental products in India. The company offers oral care products, such as toothbrushes, toothpastes, mouthwash products, whitening gels, talcum powders, sanitizers, detergents, and denture tablets. It also provides contract manufacturing services for oral care products. In addition, the company exports its products. JHS Svendgaard Laboratories Limited was founded in 1997 and is based in New Delhi, India.
Why Investors Should Care
Net profit has compounded at 29.7% per year over the last five years.
Carries low leverage with a debt-to-equity ratio of 0.09.
Recent Developments
- Mar 2026 Revenue of ₹101.69 Cr (+10.5% YoY); net profit ₹-1.92 Cr.
- Trailing 12 Months Year-on-year growth — revenue +24.6%, earnings +0.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 6.5%, profit CAGR 29.7%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 6.54% |
| 1 Year: | 24.60% |
Compounded Profit Growth
| 5 Years: | 29.68% |
| 1 Year: | 0.00% |
Stock Price Performance
| 1 Year: | -34.56% |
| 6 Months: | -11.22% |
| 3 Months: | +0.88% |
| 1 Month: | +2.04% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMABelow
- RSI (14)46.45 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Profit CAGR of 29.7% over 5 years.
CONS
- Trading 41.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Consumer Defensive).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | JHS JHS Svendgaard Laboratories Limited NSE | 7.99 | -36.32 | ₹69.84 Cr | 0.00% | -0.78% | -1.10% | 6.54% | 29.68% |
| 2 | HINDUNILVR Hindustan Unilever Limited NIFTY50NSE | 1,973.40 | 43.90 | ₹4.64 L Cr | 2.22% | 22.15% | 30.86% | 2.31% | 14.12% |
| 3 | ITC ITC Limited NIFTY50NSE | 263.50 | 16.64 | ₹3.30 L Cr | 6.07% | 36.47% | 28.53% | 3.65% | 2.54% |
| 4 | NESTLEIND Nestlé India Limited NIFTY50NSE | 1,398.00 | 70.78 | ₹2.70 L Cr | 0.86% | 62.44% | 79.99% | 17.01% | 23.05% |
| 5 | DMART Avenue Supermarts Limited NSE | 3,710.00 | 79.16 | ₹2.42 L Cr | 0.00% | 16.41% | 12.14% | 17.14% | 7.69% |
| 6 | VBL Varun Beverages Limited NSE | 405.95 | 40.51 | ₹1.37 L Cr | 0.49% | 19.44% | 16.85% | 17.26% | 26.57% |
| 7 | BRITANNIA Britannia Industries Limited NSE | 5,042.50 | 46.75 | ₹1.21 L Cr | 1.79% | 61.21% | 49.61% | 5.66% | 2.95% |
| 8 | MARICO Marico Limited NIFTY_MIDNSE | 815.15 | 55.91 | ₹1.06 L Cr | 0.49% | 38.75% | 41.85% | 11.82% | 10.61% |
| 9 | UNITDSPR United Spirits Limited NSE | 1,440.00 | 60.61 | ₹1.02 L Cr | 1.18% | 25.49% | 20.53% | 5.56% | 17.36% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in INR.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 25.17 Cr | 23.45 Cr | 22.28 Cr | 23.27 Cr | 32.70 Cr |
| Cost of Revenue | 19.43 Cr | 13.90 Cr | 13.14 Cr | 13.44 Cr | 24.75 Cr |
| Gross Profit | 5.74 Cr | 9.55 Cr | 9.14 Cr | 9.83 Cr | 7.94 Cr |
| Operating Expenses | 13.14 Cr | 9.77 Cr | 10.09 Cr | 10.06 Cr | 11.43 Cr |
| Operating Income | -7.40 Cr | -21.39 L | -95.35 L | -22.84 L | -3.48 Cr |
| EBITDA | -6.81 Cr | 2.66 Cr | 2.05 Cr | 2.26 Cr | -90.16 L |
| Interest Expense | 21.37 L | 15.67 L | 20.09 L | 27.70 L | 22.42 L |
| Pretax Income | -9.05 Cr | 62.78 L | -1.59 L | 7.98 L | -2.98 Cr |
| Tax Provision | -2.09 Cr | -42.74 L | 18.18 L | -70.90 L | 58.65 L |
| Net Income | -6.96 Cr | 1.06 Cr | -19.77 L | 78.89 L | -3.57 Cr |
| Diluted EPS | -0.84 | 0.12 | -0.02 | 0.09 | -0.42 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 84.08 Cr | 69.81 Cr | 92.00 Cr | 101.69 Cr |
| Cost of Revenue | - | 67.54 Cr | 49.45 Cr | 61.04 Cr | 65.23 Cr |
| Gross Profit | - | 16.55 Cr | 20.36 Cr | 30.96 Cr | 36.47 Cr |
| Operating Expenses | - | 31.15 Cr | 26.62 Cr | 42.92 Cr | 41.35 Cr |
| Operating Income | - | -14.60 Cr | -6.27 Cr | -11.96 Cr | -4.88 Cr |
| EBITDA | - | -16.43 Cr | 3.34 Cr | -3.99 Cr | 6.06 Cr |
| Interest Expense | - | 49.79 L | 42.49 L | 56.50 L | 85.88 L |
| Pretax Income | - | -22.95 Cr | -3.43 Cr | -12.51 Cr | -2.29 Cr |
| Tax Provision | - | -5.43 Cr | 62.91 L | 7.24 Cr | -36.81 L |
| Net Income | - | -17.52 Cr | -4.06 Cr | -19.74 Cr | -1.92 Cr |
| Diluted EPS | - | -2.23 | -0.52 | -2.37 | -0.22 |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 228.23 Cr | 197.05 Cr | 201.17 Cr | 215.22 Cr |
| Current Assets | - | 84.84 Cr | 43.66 Cr | 53.83 Cr | 63.42 Cr |
| Cash & Equivalents | - | 37.25 Cr | 4.70 Cr | 6.75 Cr | 3.75 Cr |
| Inventory | - | 13.00 Cr | 12.65 Cr | 11.88 Cr | 15.17 Cr |
| Receivables | - | 18.54 Cr | 12.88 Cr | 13.06 Cr | 16.75 Cr |
| Total Liabilities | - | 54.39 Cr | 27.17 Cr | 28.44 Cr | 40.55 Cr |
| Current Liabilities | - | 36.71 Cr | 23.34 Cr | 24.71 Cr | 32.61 Cr |
| Long Term Debt | - | 13.17 Cr | 11.89 L | 68.53 L | 5.52 Cr |
| Total Debt | - | 15.51 Cr | 5.13 Cr | 6.46 Cr | 14.85 Cr |
| Total Equity | - | 173.84 Cr | 169.88 Cr | 172.73 Cr | 174.67 Cr |
| Shares Outstanding | - | 6.49 Cr | 7.84 Cr | 8.56 Cr | 8.74 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 23.29 Cr | -9.18 Cr | -5.18 Cr | -2.66 Cr |
| Investing Cash Flow | - | 9.68 Cr | -21.14 Cr | -20.25 Cr | -11.68 Cr |
| Financing Cash Flow | - | -89.99 L | 2.17 Cr | 23.07 Cr | 11.34 Cr |
| Capital Expenditure | - | -14.34 Cr | -31.53 Cr | -10.53 Cr | -12.79 Cr |
| Free Cash Flow | - | 8.94 Cr | -40.71 Cr | -15.71 Cr | -15.45 Cr |
| Net Change in Cash | - | 32.06 Cr | -28.14 Cr | -2.36 Cr | -2.99 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 19.7% | 29.2% | 33.6% | 35.9% |
| Operating Margin % | - | -17.4% | -9.0% | -13.0% | -4.8% |
| Net Margin % | - | -20.8% | -5.8% | -21.5% | -1.9% |
| ROE % | - | -10.1% | -2.4% | -11.4% | -1.1% |
| ROCE % | - | -7.6% | -3.6% | -6.8% | -2.7% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for JHS
John Hancock Income Securities Trust (NYSE:JHS) Stock Price Crosses Below 50 Day Moving Average - What's Next? - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi9wFBVV95cUxPYWFhbmdFRlNoSzlldFE1Q3pRR0tVUU82X09hM2M5ZlN4N21wZUxGbXpNblZUVm5LWnBrSWZMTVdIOHVCZXV2cF8ydnBiYW4tX1JPOVMxMkUxeXRacnRJelFGWjRRLXZ5N3RfeUo3Yi1JRUxwV3VfcUI2a3pFTXYzVmZUQkR1eE0wYk1DV2…
JHS Svendgaard Laboratories schedules 22nd AGM for September 26 - scanx.trade
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxPS045bWE5VV9hRWptbGhNMEduRFlURHdhbzU0SlVQTnBjbzF6a2dMckEyb29TaXdTRlpWQXVpYVVlVDgzUHhQZjQtdjFBRVRnaXlNN1M5OXRkR0tveUFBcTA5WkpHUEg4ZXJDTzQtNGUxREpuOThYNmVTT1ZoU1ZWdmM5SVZud09DdlkwMU…
John Hancock Income Securities Trust (NYSE:JHS) Stock Price Passes Below 50-Day Moving Average - Time to Sell? - marketbeat.com
<a href="https://news.google.com/rss/articles/CBMi7wFBVV95cUxNS05oZWk2SlFVTklEY1VfMExoSENwclNFRllkOG5ueDF3OWVORnBWZXdwS1pPbDA2eE1aekFUOUdtakJMUVlZMXJWNy1KTGJLeGNwZU0tLUNaclhKVjhNOW9jTG1yMk1oUGpqTU1DbWdkdk1hX05iNW9ZLWtLMXRiVVhHLWJ1bDJDWmJMXz…
JHS Svendgaard Laboratories Ltd. Key Financial Ratios – Valuation, Profitability & More - Value Research
<a href="https://news.google.com/rss/articles/CBMilwFBVV95cUxOSWlfUnJQVjhMdTBoTXF5dEFDWHFKM3hnY2RjVzhPSnVmYkdPbWh1MzNUUl81Q0V0c0Z0RjJReG9yWllGQU5pTEc4MkVFSVBHby1pdV9kbGRLcDZHOThqZGNvdlBNUU5tQ1Zma2ZGVUIyQnZQazJ6TTlqREkxdmFiLTV6QkZQZUd6VjNQQn…
John (JHS) Daily Snapshot: Retreats 0.46% to $10.91 for the Current Session; Level Check: the Price Remains Bounded by the Supplied Support and Resistance - Iceberg Order - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMilwJBVV95cUxPNTcwREhGZFAzU1Mxa2ZqRFZ2XzNGMmZnR0hoRE1KTmhiY1NVY1YxM0VrLXFOMkxHcGExME55QUhiVklqTUtOanJpYkN0U1RYUHRocllCZGdJalRKT0ljQnVFZFBBSFpDTWIwM2JHZlJZMlNLS3E2YkVkdDl5VFJoTUR5UGVyQ0h6djg0LV…
JHS Svendgaard Laboratories Slips 7.4% to ₹8.29; Support at ₹7.88 in Focus - Volatility Smirk - siam.in
<a href="https://news.google.com/rss/articles/CBMisAFBVV95cUxNYnZGYkZGa1FQU2ZYbDNKV0ZqMTJWNXoxVTZNdmNnWWFPSVR3OWtiX1FDYkZ5ZW56SUZPS0h0ZURJYTFyYjVsUTVtTHpSWW1XV2VNVzkwYjE3S1FvRUxhcXFJRzhKMVljN2piNW1GSkM5SEZub2duYjhwVVAteHFiZ3BpS04tQzhoNDlyWj…
JHS — Frequently Asked Questions
What is the current share price of JHS Svendgaard Laboratories Limited (JHS)?
As of 2026-09-20 09:43 IST, JHS Svendgaard Laboratories Limited (JHS) trades at ₹7.99 on NSE. Its 52-week range is ₹6.55 to ₹13.56.
What is the market capitalisation of JHS?
JHS Svendgaard Laboratories Limited (JHS) has a market capitalisation of ₹69.84 Cr on NSE.
What is the P/E ratio of JHS?
JHS trades at a trailing price-to-earnings (P/E) ratio of -36.32. The industry average P/E is 23.14. Its price-to-book (P/B) ratio is 0.41.
What is the return on equity (ROE) of JHS?
JHS has a return on equity (ROE) of -1.10%. Its return on capital employed (ROCE) is -0.78%.
Is JHS a good stock to buy?
This page provides a data-driven analysis of JHS Svendgaard Laboratories Limited (JHS), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.